Chemical Probes logo
MRTX849 | Covalent Inhibitor of KRAS (Mutant:G12C)
RATINGS:
Cellular Use: (3 reviews)

In Model Organisms: (3 reviews)
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download

Probe Summary

More...

Targets Biochemical/Biophysical Potency Cellular Potency
KRAS (Mutant:G12C)
  • Kobs:low uM
  • IC50:14 nM; 4.7 nM (24h)
Covalent Inhibitor
up to 100 nM
up to 500 nM

Selectivity

Potency
Cellular
In Vitro

KRAS (Mutant:G12C)

Mode of Action: Covalent Inhibitor

Structure-Activity-Relationship data available? Yes

DOI Reference: 10.1021/acs.jmedchem.9b02052

In Vivo Validations

Mouse, Rat, Dog
Dose: 3 mg/Kg IV, 3 to 100 mg/Kg PO
Route of delivery: Intravenous, Oral
Plasma half life: 1.51 (M), 2.57 (R), 7.56 (D) h
Systemic clearance: 19.9 (M), 44.2 (R), 29.6 (D) ml/min/kg
Target engagement assay: Anti-tumor activity of MRTX849 was evaluated in a MIA PaCa-2 xenograft model.

DOI Reference: 10.1021/acs.jmedchem.9b02052

Negative Control Compounds

Compound-21

Orthogonal Probes def

ARS-1620
AMG-510

Chemical Information

Molecular Formula C32H35ClFN7O2
SMILEs C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
InChI InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1
Molecular weight 603.25 Da
AlogP 4.732980000000004
HBond acceptors 9
HBond donors --
Atoms 78

Vendors

Note: This is not an exhaustive list and does not indicate endorsement by the portal.

Expert Reviews

by SERP
(on 25 Jul 2020)
Cellular Use Rating
In Model Organisms
(The reviewer did not leave any public comments)
by SERP
(on 4 Aug 2020)
Cellular Use Rating
In Model Organisms
MRTX849 is a very potent and selective inhibitor of kRas G12C. Along with AMG-510 this compound is one of the first to proceed through clinical development showing benefit in certain tumor types that...
by SERP
(on 5 Sept 2020)
Cellular Use Rating
In Model Organisms
MRTX849: - Is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C presently undergoing phaseI/II clinical trials in patients with non-small cell lung cancer. MRTX849...
Note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars. Read more about our evaluation criteria